Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
China · Delayed Price · Currency is CNY 29.53
-0.05 (-0.17%)
Mar 30, 2026, 11:29 AM CST
SHA:688639 Revenue
In the year 2025, Anhui Huaheng Biotechnology had annual revenue of 2.86B CNY with 31.40% growth. Anhui Huaheng Biotechnology had revenue of 668.30M in the quarter ending December 31, 2025, with 4.60% growth.
Revenue
2.86B
Revenue Growth
+31.40%
P/S Ratio
2.58
Revenue / Employee
1.31M
Employees
2,191
Market Cap
7.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.86B | 683.90M | 31.40% |
| Dec 31, 2024 | 2.18B | 239.67M | 12.37% |
| Dec 31, 2023 | 1.94B | 519.62M | 36.63% |
| Dec 31, 2022 | 1.42B | 464.56M | 48.69% |
| Dec 31, 2021 | 954.10M | 466.85M | 95.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 2.81B |
| Youcare Pharmaceutical Group | 2.45B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shanghai Medicilon | 1.08B |
| Wuhan Keqian Biology Co.,Ltd | 950.29M |
| Acrobiosystems | 794.52M |
| Daan Gene | 765.48M |